+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins

Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins

Plos one 10(9): E0138332

There exists a subpopulation of T2DM in whom first-line doses of statin are insufficient for optimally reducing LDL-C, representing a major risk of CVD. The RESEARCH study focuses on LDL-C reduction in this population along with modifications of the lipid profiles leading to residual risks. Lipid changes were assessed in a randomized, multicenter, 12-week, open-label study comparing a high-potency statin (10mg of atorvastatin or 1mg of pitavastatin) plus ezetimibe (EAT: n = 53) with a double dose of statin (20mg of atorvastatin or 2mg of pitavastatin) (DST: n = 56) in DM subjects who had failed to achieve the optimal LDL-C targets. Lipid variables were compared with a primary focus on LDL-C and with secondary focuses on the percentage of patients who reached the LDL-C targets and changes in the levels of RLP-C (remnant like particle cholesterol) and sd-LDL-C, two characteristic atherogenic risks of DM. The reduction of LDL-C (%), the primary endpoint, differed significantly between the two groups (-24.6 in EAT vs. -10.9 in DST). In the analyses of the secondary endpoints, EAT treatment brought about significantly larger reductions in sd-LDL-C (-20.5 vs. -3.7) and RLP-C (-19.7 vs. +5.5). In total, 89.4% of the patients receiving EAT reached the optimized treatment goal compared to 51.0% of the patients receiving DST. The changes in TC (-16.3 vs. -6.3) and non-HDL-C (-20.7 vs. -8.3) differed significantly between the two groups. Ezetimibe added to high-potency statin (10 mg of atorvastatin or 1 mg of pitavastatin) was more effective than the intensified-dose statin (20 mg of atorvastatin or 2 mg of pitavastatin) treatment not only in helping T2DM patients attain more LDL-C reduction, but also in improving their atherogenic lipid profiles, including their levels of sd-LDL-C and RLP-C. We thus recommend the addition of ezetimibe to high-potency statin as a first line strategy for T2DM patients with insufficient statin response. The UMIN Clinical Trials Registry UMIN000002593.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057694650

Download citation: RISBibTeXText

PMID: 26398887

DOI: 10.1371/journal.pone.0138332

Related references

Po187 Rapid Glucose Lowering Effect Of Sitagliptin In Poorly Controlled Type 2 Diabetic Patients (Sunshine Study). Diabetes Research and Clinical Practice 106: S142-S143, 2014

Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Metabolism: Clinical and Experimental 55(5): 599-604, 2006

Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. Journal of the American Heart Association 4(10): E001675, 2015

Anti-diabetic and antioxidant effect of cinnamon in poorly controlled type-2 diabetic Iraqi patients: A randomized, placebo-controlled clinical trial. Journal of Intercultural Ethnopharmacology 5(2): 108-113, 2016

Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinology and Metabolism Clinics of North America 38(1): 79-97, 2009

Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial. Circulation Journal 77(7): 1791-1798, 2013

Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Current Medical Research and Opinion 23(9): 2183-2192, 2007

The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34(4): 246-252, 1991

Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. International Journal of Clinical Practice 60(8): 906-910, 2006

Eating behavior among type 2 diabetic patients: a poorly recognized aspect in a poorly controlled disease. Review of Diabetic Studies 3(1): 11-16, 2006

Two-year effect of rosiglitazone in chinese poorly controlled type 2 diabetic patients. Chang Gung Medical Journal 29(5): 486-492, 2007

Consistency of LDL-C lowering effect across subgroups of ezetimibe co-administered with statins. European Heart Journal 23(Abstract Suppl.): 19, August-September, 2002

Atherogenic lipoprotein profiles in Niemann-Pick type A and B patients and obligate heterozygotes. Pediatric Research 47(4 Part 2): 246A, 2000

Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients. Cureus 10(7): E3030, 2018

Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes. Journal of Vascular Surgery 49(4): 1083-1084, 2009